Astonea Labs
- Market cap
- ₹ 340 Cr.
- P/E
- 75.1x
- P/B
- 5.94x
- 52-week range
- 118 – 369
- ROE
- 12%
- ROCE
- 11%
- Dividend yield
- 0%
- Debt / equity
- 0.75
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE SME
About
Astonea Labs Limited is an India-based company, which specializes in the manufacturing and marketing of a range of pharmaceutical and cosmetic products. These include antibiotic drugs, anti-cold medications, antihistamines, and drugs for diabetes, cardiovascular diseases, gynecological concerns, analgesics, fungal infections, and multivitamins. The Company also offers products for skin, tooth, and hair care, available in various forms, such as gels, ointments, creams, lotions, oils, and serums. Additionally, the Company is also involved in the trading of certain packing materials and raw materials used in pharmaceutical and cosmetic products. It manufactures and markets its own products under the brands Glow Up and Regero in the domestic market, wherein the products under Glow Up are also available through e-commerce platforms like Amazon and Tata 1MG. The Company also exports its products directly to countries such as Iraq and Yemen.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Astonea Labs against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)75.1 against a typical 34.3: pricier than most peers (1st = cheapest).178th of 220
- Share price, 3 months+18% against a typical −0.5%.39th of 200
- Size₹ 339.5 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).107th of 199
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2024 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 47 | 66 | 81 |
| Expenses | 41 | 61 | 73 |
| Operating Profit | 7 | 5 | 8 |
| OPM % | 14% | 8% | 10% |
| Other Income | 0 | 0 | 0 |
| Interest | 2 | 2 | 2 |
| Depreciation | 2 | 2 | 3 |
| Profit before tax | 3 | 2 | 4 |
| Tax % | 24% | 20% | 20% |
| Net Profit | 2 | 1 | 3 |
| EPS in Rs | 2.76 | 1.35 | 2.95 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 30%
- TTM
- 51%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 97%
- TTM
- −16%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 19%
- 3 Years
- 22%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Astonea Labs | ₹ 323.00 | ₹ 340 Cr. | 75.1x | 5.9x | 12% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 34.6x | 5x | — | 19.8% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 91.9x | 14.4x | — | 26.1% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 69.6x | 18.4x | — | 13.7% |
| Laurus Labs | ₹ 1,974.00 | ₹ 1,06,658 Cr. | 125.1x | 21.1x | — | 15% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 20.6x | 4.1x | — | 15.7% |
Management
- Sumit Kumar
- Chief Financial Officer
- Ankit Kapoor
- Company Secretary and Compliance Officer
- Ashish Gulati
- Managing Director, Executive Director
- Pardeep Singh
- Executive Director
- Pooja Singh
- Additional Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.